A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report.
D. C. Cho
No relevant relationships to disclose
E. I. Heath
No relevant relationships to disclose
J. M. Cleary
No relevant relationships to disclose
E. L. Kwak
Research Funding - Synta
L. Gandhi
No relevant relationships to disclose
D. P. Lawrence
No relevant relationships to disclose
C. Zack
No relevant relationships to disclose
F. Teofilovici
Employment or Leadership Position - Synta
Stock Ownership - Synta
R. Bradley
Employment or Leadership Position - Synta
Stock Ownership - Synta
M. D. Karol
Employment or Leadership Position - Synta
Stock Ownership - Synta
G. Shapiro
Research Funding - Synta
P. LoRusso
Research Funding - Synta